- Home
- CERO vs DRCT Comparison
CERO vs DRCT Comparison
Compare CERO & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- DRCT
- Stock Information
- Founded
- CERO 2017
- DRCT 2018
- Country
- CERO United States
- DRCT United States
- Employees
- CERO N/A
- DRCT N/A
- Industry
- CERO
- DRCT Computer Software: Programming Data Processing
- Sector
- CERO
- DRCT Technology
- Exchange
- CERO Nasdaq
- DRCT Nasdaq
- Market Cap
- CERO 9.6M
- DRCT 9.2M
- IPO Year
- CERO N/A
- DRCT 2022
- Fundamental
- Price
- CERO $8.25
- DRCT $0.45
- Analyst Decision
- CERO Strong Buy
- DRCT Strong Buy
- Analyst Count
- CERO 2
- DRCT 1
- Target Price
- CERO $45.00
- DRCT $6.00
- AVG Volume (30 Days)
- CERO 40.2K
- DRCT 768.9K
- Earning Date
- CERO 08-29-2025
- DRCT 08-05-2025
- Dividend Yield
- CERO N/A
- DRCT N/A
- EPS Growth
- CERO N/A
- DRCT N/A
- EPS
- CERO N/A
- DRCT N/A
- Revenue
- CERO N/A
- DRCT $36,459,000.00
- Revenue This Year
- CERO N/A
- DRCT $50.71
- Revenue Next Year
- CERO N/A
- DRCT $26.31
- P/E Ratio
- CERO N/A
- DRCT N/A
- Revenue Growth
- CERO N/A
- DRCT N/A
- 52 Week Low
- CERO $6.71
- DRCT $0.38
- 52 Week High
- CERO $895.40
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- CERO 49.24
- DRCT 46.20
- Support Level
- CERO $8.07
- DRCT $0.38
- Resistance Level
- CERO $8.90
- DRCT $0.47
- Average True Range (ATR)
- CERO 0.40
- DRCT 0.05
- MACD
- CERO 0.11
- DRCT -0.00
- Stochastic Oscillator
- CERO 59.38
- DRCT 26.17
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.